We are testing a new engineered T-cell therapy, UCART22, for patients with relapsed or refractory B-ALL. The study aims to evaluate its safety and effectiveness, especially for those who have not responded to other therapies.
Health conditions and diseases that the clinical trial is designed to study and treat.
Relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of immature white blood cells. This condition occurs when the leukemia returns after treatment or does not respond to initial therapy.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
